The U.S. government has released its 2026 Medicare Advantage and prescription drug plan quality ratings, offering insight into how major health insurers performed in providing care to seniors. These annual ratings, issued by the Centers for Medicare & Medicaid Services (CMS), play a key role in determining bonus payments to insurers—worth hundreds of millions or even billions of dollars—and influence plan revenues in 2027.
According to CMS data, CVS Health’s Aetna stands out with over 81% of members enrolled in top-rated plans, while UnitedHealth Group follows closely with 78%. Elevance Health improved significantly, reaching 55% of members in 4-star or higher plans, compared to 40% last year. In contrast, Humana saw only about 20%, or 1.2 million members, in highly rated plans.
Overall, 64% of all Medicare Advantage members with prescription drug coverage are enrolled in plans rated four stars or higher, according to Oppenheimer analysts. These ratings assess factors such as customer satisfaction, access to care, chronic disease management, and preventive health screenings, ensuring seniors can make informed choices when selecting coverage.
CVS Health said more than 63% of its Aetna Medicare Advantage members are in 4.5-star plans for next year. Meanwhile, UnitedHealth reported that 40% of its members are enrolled in 4.5-star or higher plans, consistent with its earlier projections. Analysts described this year’s results as largely expected, following recent company updates.
Centene’s Wellcare, led by CEO Michael Carson, also reported continued improvement, emphasizing the company’s focus on delivering high-quality, affordable healthcare and enhancing health outcomes nationwide.
As competition intensifies, star ratings continue to shape the landscape of the Medicare Advantage market, rewarding insurers that excel in quality and member satisfaction while motivating others to raise their standards.


CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
K+S Raises 2026 Earnings Outlook After Strong Q1 Results
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Reliance Industries Reworks Jio IPO Into Fresh Share Sale Amid Valuation Talks
Why the future of marijuana legalization remains hazy despite high public support
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 



